Clinical Trial Update: A Phase 1, Randomized, Placebo-controlled, Dose-escalation Safety Study of MEDI4212 in Subjects With IgE >= 30 IU/mL [Phase 1]

View source ↗

Summary

Phase 1 randomized, placebo-controlled, dose-escalation safety study of MEDI4212 in subjects with IgE ≥ 30 IU/mL has completed and results have been posted. The…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Allergic Asthma
• Atopic Dermatitis

Drugs mentioned

• MEDI4212

Snippet

Sponsor: MedImmune LLC | Conditions: Allergic Asthma, Atopic Dermatitis | Phase 1 | Status: COMPLETED | Results posted: 2014-12-30